Cholesterol synthesis inhibition or depletion in axon regeneration

Abstract
Cholesterol is biosynthesized by all animal cells. Beyond its metabolic role in steroidogenesis, it is enriched in the plasma membrane where it has key structural and regulatory functions. Cholesterol is thus presumably important for post-injury axon regeneration, and this notion is supported by studies showing that impairment of local cholesterol reutilization impeded regeneration. However, several studies have also shown that statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, are enhancers of axon regeneration, presumably acting through an attenuation of the mevalonate isoprenoid pathway and consequent reduction in protein prenylation. Several recent reports have now shown that cholesterol depletion, as well as inhibition of cholesterol synthesis per se, enhances axon regeneration. Here, I discussed these findings and propose some possible underlying mechanisms. The latter would include possible disruptions to axon growth inhibitor signaling by lipid raft-localized receptors, as well as other yet unclear neuronal survival signaling process enhanced by cholesterol lowering or depletion.

Key Words: axon regeneration; cholesterol; 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase); lipid raft; methyl-β-cyclodextrin; Nogo receptor; prominin-1; RhoA; statins

Introduction
Cholesterol is a key metabolite produced in all animal cells and is a precursor to a plethora of steroidol molecules, such as steroid hormones (Miller, 2017). It is also a membrane lipid component and a key determinant of membrane fluidity (Subczynski et al., 2017). Particularly enriched in the plasma membrane, it is important for the structure and function of plasma membrane lipid rafts (Levental et al., 2020; Sviridov et al., 2020), which are cell surface microdomains important for protein trafficking, targeting and signal transduction. Among mammalian organs, the brain contains the largest amount of cholesterol, where it is critical for processes such as myelination (Safer and Stumpf, 2015). In the central nervous system (CNS), adequate cholesterol biosynthesis and delivery in neurons is likely to be indispensable for neuronal structure and function. In the autosomal recessive Niemann-Pick disease type C (NPC) (Hammond et al., 2019), for example, defects in intracellular cholesterol trafficking results in neurodegeneration. Even heterozygous mutations of NPC gene that do not cause disease may be associated with late-onset neurodegenerative disorders (Schneider et al., 2019).

In adult mammals, axon regeneration by neurons in the peripheral nervous system occurs more readily compared to those in the CNS upon injury. This is due at least partly to the presence of inhibitory factors in the adult CNS myelin (Yiu et al., 2006; Uyeda and Muramatsu, 2020) and extracellular matrix (Quraishe et al., 2018). Axon regeneration upon injury by both peripheral and central neurons requires formation and extension of functional growth cones and means of driving the extension of growing axon tips (Rodemer et al., 2020). This would necessitate specific trafficking and targeting of proteins and lipids to the growing axon tip. Some lipids, such as phosphatidylcholine, can be synthesized at the axon (Vance et al., 1991), but cholesterol needs to be transported to the axon from the neuronal soma (Vance et al., 2000). Early evidence based on compartmented cultures of rat sympathetic neurons in vitro indicated that neuronal cholesterol synthesis inhibition without any exogenous lipid supply impairs axon growth (de Chaves et al., 1997). In vivo, complete nerve repair would also require axonal remyelination. In the CNS, oligodendrocytes elevate their cholesterol levels to facilitate the synthesis of new myelin membranes (Safer and Simons, 2010). In this regard, a functional complementary screening for pro-regenerative factors of olfactory ensheathing cells have identified that SCARB2 (Ruet et al., 2013), which encodes the lysosomal integral membrane protein 2, works in parallel with neuronal NPCs in lysosomal cholesterol export (Heybrock et al., 2019). Axon regeneration was in fact shown to be more sensitive than myelination to manipulations that impaired local cholesterol reutilization after rat sciatic nerve crush (Goodrum et al., 2000).

While all the above attests to the importance of cholesterol in axonal outgrowth and regeneration, there are also findings that suggest that a reduction of cholesterol levels may promote axon regeneration post-injury in both the peripheral nerves and the CNS. Upon rat sciatic nerve crushes, cholesterol synthesis is drastically downregulated post-injury and surprisingly also during nerve regeneration (Goodrum, 1990). Inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (EC 2.3. 3.10), the rate-determining enzyme of cholesterol biosynthesis, promoted neurite outgrowth of rat embryonic cortex explants or postnatal spinal cord explants even on an axon growth inhibitory myelin substrate (Holmberg et al., 2006). Some recent reports have now reaffirmed the notion that axon regeneration could indeed be promoted by cholesterol depletion or cholesterol synthesis inhibition. A search of PubMed (https://pubmed.ncbi.nlm.nih.gov/)

How to cite this article: Tang BL (2022) Cholesterol synthesis inhibition or depletion in axon regeneration. Neural Regen Res 17(2):271-276.
with the key words “cholesterol” and “axon regeneration” uncovered these and related earlier reports (Table 1). We shall first look at these results before pondering on the possible underlying mechanisms.

Table 1  A tabulated summary of studies indicating that cholesterol synthesis inhibition or cholesterol depletion could enhance axon regeneration

| Study                              | Experimental system/model | Methods of cholesterol level manipulation |
|------------------------------------|---------------------------|-------------------------------------------|
| Holmberg et al., 2006              | Rat embryonic cortex explants or postnatal spinal cord explants | Simvastatin                                 |
| Tassew et al., 2014                | Chick retinal explants, rat spinal cord compression model | Methyl-β-cyclodextrin (MβCD),Blocking Neogenin lipid raft association with a Ig-like domain peptide |
| Whitton et al., 2015               | Dissociated mouse spiral ganglia | Cervastatin                                 |
| Li et al., 2016                    | Mouse embryonic stem cell-derived motor neurons | Simvastatin                                 |
| Roselló-Busquets et al., 2019      | Dissociated hippocampal neurons, organotypic slice cultures, sciatric nerve axotomy | MβCD, Nystatin or Cholesterol oxidase |
| Roselló-Busquets et al., 2020      | Hippocampal explants | Nystatin                                    |
| Shabanzadeh et al., 2021           | Chick retinal explant, rat optic nerve crush | Lovostatin, geranylgeranyl pyrophosphate, Δ-7-sterol reductase inhibitors AY9944, BM15766 and silencing of Δ-7-sterol reductase expression |

Evidence for the Promotion of Axon Regeneration by Cholesterol Synthesis Inhibition

One of the first indications that cholesterol synthesis inhibition may promote axon regeneration came from drug screening data indicating that statins, a class of HMG-CoA reductase inhibitor, promoted neurite outgrowth and axon regeneration (Whitton et al., 2015; Li et al., 2016). A high content screen of 440 compounds from the NIH Clinical Collection using dissociated mouse spinal ganglia as a neurite outgrowth model has identified a single lead in cerivastatin (CAS 145599-86-6) (Whitton et al., 2015). In a larger high-throughput screen using mouse embryonic stem cell-derived motor neurons of 50,401 compounds, simvastatin (CAS 79902-63-9) was found to be the most potent lead (Li et al., 2016).

Other modes of lowering or depleting cholesterol levels have the same axon regeneration promoting effect. Monnier’s group, for example, has shown that modification of growth cone lipid rafts could promote axon regeneration after spinal cord injury and optic nerve crush (Tassew et al., 2014). This could be achieved using methyl-β-cyclodextrin (MβCD, CAS 128446-36-6) to deplete membrane cholesterol and disrupt cholesterol-rich lipid rafts. A peptide corresponding to the four immunoglobulin-like domains of neogenin (De Vries and Cooper, 2008), which disrupted the interaction between neogenin and the axon growth inhibitor repulsive guidance molecule-a (RGMa) (Hata et al., 2006) at lipid rafts, could also promote axon outgrowth (Tassew et al., 2014). Another recent report by Roselló-Busquets and colleagues showed that Nystatin (CAS 1400-61-9), a cholesterol-binding compound that could extract cholesterol from membranes, promoted axon growth in mice hippocampal explants (Roselló-Busquets et al., 2020). The group also showed that cholesterol depletion by either MβCD, Nystatin or the enzyme cholesterol oxidase (EC 1.1.3.6) enhanced the growth cone morphology of CNS hippocampal and cerebellar external granular layer neurons, as well as the peripheral nervous system dorsal root ganglion (DRG) neurons (Roselló-Busquets et al., 2019), and promoted neurite extension in the latter. Nystatin treatment also enhanced axon regeneration of axotomized E16 hippocampal neurons and organotypic co-cultures. MβCD administered at a non-toxic dose to mice altered the integrity of lipid raft structure in DRG neurons, and increased the expression of the axonal regeneration factor growth-associated protein 43 (Denny, 2006) after sciatic nerve resection, with improved muscle re-innervation and sensory recovery (Roselló-Busquets et al., 2019).

A more recent report by the Monnier group further showed that inhibition of cholesterol synthesis per se could promote axon outgrowth by neurons in retinal explants (Shabanzadeh et al., 2021). Interestingly, and contrary to earlier work (Li et al., 2016), the HMG-CoA reductase inhibitor Lovastatin (CAS 75330-75-5) is found to significantly inhibit axonal outgrowth on the permissive substrate laminin, and this inhibition could be reversed by the protein prenylation substrate geranylgerany pyrophosphate (GGPP) (CAS 313263-08-0). On the other hand, two inhibitors of Δ-7-sterol reductase (EC 1.3.1.121) that act at a late-stage of cholesterol synthesis downstream of the HMG-CoA reductase (AY9944 (CAS 366-93-8) and BM15766 (CAS 86621-92-3)), did not alter normal axon growth on laminin compared to control. Axon outgrowth on the inhibitory substrates myelin or RGMa was not affected either way by lovastatin alone, but addition of GGPP enhanced its axon outgrowth promoting effect. Importantly, axon outgrowth on myelin is also enhanced by the late-stage of cholesterol synthesis inhibitors. These results suggest that inhibition of cholesterol synthesis per se, not so much the inhibition of protein prenylation, underlies the promotion axon outgrowth on inhibitory substrates. In fact, any axon outgrowth or regeneration promoting effect of statins on non-permissive substrate could be potentially masked by a retardation of axon growth due to protein prenylation inhibition.

Is inhibition of cholesterol synthesis per se beyond those steps that generate isoprenoids able to directly promote axon regeneration? The authors showed that treatment of chick brains with either AY9944, lovastatin, or lovastatin + GGPP altered lipid raft formation and neogenin localization. Importantly, either AY9944 or lovastatin in combination with GGPP (but not either of the latter alone) enhanced axonal regeneration after optic nerve injury. Furthermore, siRNA-mediated knockdown of Δ-7-sterol reductase, the final enzyme in the cholesterol synthesis pathway that converts 7-dehydrocholesterol to cholesterol, also promoted axon regeneration. Interestingly, beyond promoting axonal outgrowth, cholesterol inhibition also enhanced retinal ganglion cell survival after optic nerve crush, as well as photoreceptor neuron survival in a mouse model of Retinitis Pigmentosa (Shabanzadeh et al., 2021).

In another study, Lee et al. (2020) showed that prominin-1 (or CD133) (Barzegar Behrooz et al., 2019), a stem cell marker that is developmentally downregulated in mouse DRG neurons, is an intrinsic factor required for axon regeneration. In vivo, DRG neurons of Prom1 knockout (KO) mice have impaired regeneration from sciatic nerve crushes, and Prom1 KO neurons displayed significant defects in axon regrowth after injury incurred by re-plating in culture. Exogenous over-expression of human PROM1 in the mice prom1 KO neurons significantly enhanced axon growth after re-plating, even on an inhibitory substrate of the CNS chondroitin sulfate proteoglycans (CSPGs) (Silver and Silver, 2014). Furthermore, adeno-associated virus-mediated delivery of prom1 in mice enhanced sciatic nerve regeneraton after injury. Transcriptional profiling of embryonic DRG neurons with or without PROM1 overexpression revealed that prom1-differentially expressed genes are nervous system enriched,
but showed only a modest overlap with injury responsive genes. Gene ontology analysis however found that some of the differentially expressed genes are lipid and sterol metabolic genes that were consistently downregulated with prom1 over-expression. In this regard, prom1 is shown to interact with the type 1 transforming growth factor-β receptor and is required for injury-induced Smad2 phosphorylation and Smad-dependent transcriptional changes, with its downregulation of cholesterol synthesis effected via Smad signaling (Orlova et al., 2016).

Possible Mechanisms Underlying the Role of Cholesterol Depleting or Cholesterol Synthesis Inhibition in Promoting Axon Regeneration

The recent results summarized above suggest that a reduction in cholesterol promotes axon outgrowth during regeneration, but how does cholesterol lowering produce this effect? A possible mode of action of statin could have been the result of a blanket inhibition of all mevalonate-based isoprenoid synthesis and consequential attenuation of protein prenylation (Figure 1). A combined inhibition of the prenylation enzymes farnesyltransferase (EC 2.5.1.58) and geranylgeranyl transferase type I (EC 2.5.1.59) is known to recapitulated statins’ promotion of axon growth on an inhibitory substratum (Li et al., 2016). The well-known axonal growth inhibitory role of the small GTPase RhoA and its effector Rho-associated coiled kinase (ROCK) (Fujita and Yamashita, 2014), which is central to the axonal growth cone growth inhibition or collapsing activity of many myelin-associated inhibitors (Eftekharpour et al., 2017), is dependent on proper C-terminal prenylation of Rho (Reddy et al., 2020). Attenuation of the RhoA-ROCK-mediated growth cone growth inhibitory activity by a reduction in prenylation would thus appear to be particularly relevant for cholesterol lowering-enhanced axonal regrowth in the injured CNS.

However, a major caveat of this interpretation is that inhibition of protein prenylation would be rather indiscriminate. All small GTPases and other molecules that require prenylation for their function will be affected, including some of the pro-regenerative Rac1 (Liu et al., 2018; Scott-Solomon and Kuruvilla, 2020) and Rab family members (Villardero-Campos et al., 2016). Attesting to this possibility, the results of Shabanzadeh et al. (2021) showed that lovastatin inhibited axon outgrowth on permissive substrates, and did not help outgrowth on myelin unless prenylation defect is first rescued by GGPP. That either A-7-sterol reductase inhibitors or its expression silencing were able to promote axon regeneration would suggest that cholesterol reduction per se underlies the axon outgrowth promoting effects. This notion would be consistent with the other observations, where direct cholesterol depletion by pharmacological agents such as MβCD and Nystatin (Tassew et al., 2014; Roselló-Busquets et al., 2019, 2020) could also promote axon outgrowth or regeneration. Can this result be reconciled with previous data indicating that statins could enhance axon regeneration? It is notable that the lactone prodrug form of lovastatin has differing effects on axon regeneration compared to the ‘activated’, hydroxyl acid form (Shabanzadeh et al., 2021). The former significantly promoted axon growth on RGMa substrate compared to controls, but unlike the latter, this axon outgrowth promoting activity is reduced and not enhanced by GGPP. The lactone prodrug form of lovastatin may thus have axon growth promoting activities beyond HMG-CoA reductase inhibition, likewise other statin class of compounds and their various derivatives.

How exactly does a reduction in axonal or growth cone cholesterol per se promote axon outgrowth? Given the fundamental importance of cholesterol to plasma membrane structure and function, the answer to this question may not be intuitively obvious, but the following may be plausible (Figure 2). Cholesterol content is a determinant of membrane fluidity, and it is possible that alterations in growth cone plasma membrane fluidity will influence axon outgrowth. This point may be particularly relevant for the extension of injured axons in adult neurons, as it has been hypothesized that regeneration of these may not involve the typical actin-myosin molecular motors that guide embryonic growth cones extension in developing axons. Rather, non-growth cone-mediated axon elongation mechanisms may be at work in extending injured axons in the mature CNS (Rodemer et al., 2020), and these may be aided, albeit in yet unclear ways, by an increase in membrane fluidity.

Cholesterol is enriched in lipid rafts, which are important for plasma membrane protein trafficking and targeting. Disruption of lipid rafts at the growth cone affects particularly the plasma membrane targeting of Glycosyl-phosphatidylinositol (GPI)-anchored proteins. In this regard, it is notable that the Nogo-66 receptor family of proteins (NgR1-3) (Porrie et al., 2012), which transduces growth inhibitory signals from myelin-associated inhibitory proteins such as Nogo-A, Myelin-associated glycoprotein (Wong et al., 2002), oligodendrocyte-myelin glycoprotein (Wang et al., 2002) and CSPGs (Dickendesher et al., 2012), are GPI-anchored proteins. Furthermore, the NgR co-receptor, p75NTR, could also be localized at lipid rafts (Higuchi et al., 2003). With cholesterol depletion leading to lipid raft disruption, a reduced targeting of NgRs to the growth cone surface would conceivably enhance axon outgrowth. NgRs are indeed segregated into lipid rafts in rat brain and Nogo-66 signaling has been shown to be inhibited by cholesterol depletion (Yu et al., 2004). In the same vein of thought, neogenin is also recruited to and interacts with the axonal growth inhibitor RGMa at lipid rafts, and the disruption of this interaction promoted axon outgrowth (Tassew et al., 2014).

It would also be interesting to see if cholesterol depleting or synthesis inhibition impairs targeting or expression of other receptors for axon outgrowth inhibitors. These would include the other Nogo receptors paired immunoglobulin-like receptor B (Atwal et al., 2008), and sphingosine 1-phosphate receptor 2 (Kempf et al., 2014), as well as the CSPG receptors protein tyrosine phosphatase σ (Shen et al., 2009) and leukocyte common antigen-related phosphatase (Fisher et al., 2011). Paired immunoglobulin-like receptor B in particular has been shown to act in terms of axon outgrowth inhibition in association with p75NTR (Fujita et al., 2011), while members of the protein tyrosine phosphatase family are known to be localized to lipid rafts (Caseli et al., 2002). Furthermore, growth cone repulsive molecules such as Semaphorin 7A and Ephrin-A are also GPI-anchored proteins (Um and Ko, 2017). These repulsive axon guidance molecules tend to be upregulated after injury and could contribute to inhibition of axon regeneration (Coulthard et al., 2012; Kopp et al., 2010). Cholesterol depletion and disruption of lipid rafts may also diminish their axon regeneration inhibitory effect.

Lipid rafts are also signaling hubs for a number of growth signaling receptors (Mollinedo and Gajate, 2020). In this context, it is notable that Nystatin treatment of hippocampal neurons seems to promote Akt phosphorylation and increase nitric oxide levels (Roselló-Busquets et al., 2020). The basis for these events are at present unclear, although these may be a consequence of perturbed growth receptor signaling processes that are otherwise more regulated or confined. These lipid raft disruption-enhanced signaling events may result in expression of axon outgrowth promoting factors such as growth-associated protein 43, and could also explain why cholesterol depletion promoted not just axon outgrowth, but also neuronal survival (Shabanzadeh et al., 2021), another key feature for successful regeneration. Neogenin’s recruitment to lipid raft is dependent on bone morphogenetic protein (BMP)-
mediated signaling that could be antagonised by noggin (Tassew et al., 2014). BMPs are members of the transforming growth factor-β superfamily, and canonical signalling from BMP and their receptors occurs via Smads (Orlova et al., 2016). This appears to be somewhat connected with the finding on Prom1-regulated Smad signalling which resulted in reduction in cholesterol synthesis and axon outgrowth (Lee et al., 2020). Further work would be required to properly resolve and clarify these connections, as well as the basis of enhanced pro-survival signaling resulting from cholesterol depletion.

**Implications and Caveats**

The recent findings discussed above suggest that cholesterol depletion or synthesis inhibition promotes axon regeneration, at least for neurons in vitro and in rodent models. The findings also implied that cholesterol depletion or inhibition of its synthesis is exploitable in therapeutic approaches for the enhancement of axon (particularly those of CNS neurons) regeneration after injury, either by pharmacological or genetic manipulations. It is conceivable that either systemic or localized/carrier-targeted delivery of cholesterol depleting compounds, or a combination thereof, could be beneficial for axon regeneration in peripheral or CNS nerve lesions. This would also be somewhat in line with the notion that dysregulated cholesterol homeostasis contributes to several neurodegenerative diseases (Dai et al., 2021), such as Alzheimer’s disease (Sáiz-Vazquez et al., 2020; Samant and Gupta, 2020), Parkinson’s disease (García-Sanz et al., 2020) and Huntington’s disease (González-Guevara et al., 2020). Cholesterol lowering drugs such as statins do have demonstrated benefits in some of the neurodegenerative disease models in animals (Saeedi Saravi et al., 2017; Langness et al., 2021).

However, several caveats should be heeded for the notions above. One of these would pertain to the effects any treatment might have on the different cell types at the injury/regenerating site. While specific cholesterol depletion from axonal growth cones may enhance axon outgrowth, its depletion from oligodendrocytes may impair myelination. One also needs to be mindful of cholesterol’s essential structural and biochemical functions, and remember that targeted disruption of the gene encoding HMG-CoA reductase resulted in early embryonic lethality in mice (Ohashi et al., 2003). It is conceivable that a drastic or severe reduction of cholesterol would have systemically or neuronal specific detrimental effects. A threshold amount of cholesterol would likely be important for the proper functioning of key signaling molecules that modulates neuronal function and survival.

Beyond the obvious need for sufficient cholesterol to avoid hypomyelination, two other examples below portray a need for the maintenance of sufficient cholesterol in neurons. Firstly, cholesterol is known to modulate synaptic transmission (Krivoi and Petrov, 2019; Korinek et al., 2020) and changes in cholesterol levels could thus affect synaptic strength and plasticity (Wang and Zheng, 2015). Secondly, the activity and signaling of Sonic hedgehog (Chen et al., 2018), which is important for neuronal survival, neurogenesis and neural regeneration (Yamada et al., 2018; Dobbs et al., 2019), is critically dependent on its covalent modification by cholesterol (Ribó, 2012). Any therapeutic manipulation of cholesterol levels to promote axon regeneration would need to be carefully weighted and precisely executed. Much more therefore remains to be learned before this approach can become clinically translatable.

**Author contributions:** BLT wrote the manuscript and approved the final version of the manuscript.

**Conflicts of interest:** The author declares no conflicts of interest.

**Financial support:** None.

**Copyright license agreement:** The Copyright License Agreement has been signed by the author before publication.

**Plagiarism check:** Checked twice by iThenticate.

**Peer review:** Externally peer reviewed.

**Open access statement:** This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix,
tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier-Lavigne M (2008) PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 322:967-970.

Barzegar Behrozou A, Syahir A, Ahmad S (2019) CD133: beyond a cancer stem cell biomarker. J Drug Target 27:257-269.

Borrie SC, Baeumer BE, Bandtlow CE (2012) The Nogo-66 receptor family in the intact and diseased CNS. Cell Tissue Res 349:105-117.

Caselli A, Mazzinghi B, Camici G, Manaog G, Rampogi G (2002) Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem Biophys Res Commun 296:692-697.

Chen SD, Yang J-L, Hwang WC, Yang DI (2018) Emerging roles of Sonic hedgehog in adult neurological diseases: Neurogenesis and beyond. Int J Mol Sci doi:10.3390/ijms19082423.

Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M, Boyd AW (2012) Eph/Ephrin signaling in injury and inflammation. Am J Pathol 181:1493-1503.

Dai L, Zou L, Meng J, Qiang G, Yan M, Zhang Z (2021) Cholesterol metabolism in neurodegenerative diseases: Molecular mechanisms and therapeutic targets. Mol Neurobiol doi:10.1007/s12035-020-02232-6.

de Chaves EI, Ruisiñol AE, Vance DE, Campenot RB, Vance JE (1997) Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J Biol Chem 272:30766-30773.

De Vries M, Cooper HM (2008) Emerging roles for neogenin and its ligands in CNS development. J Neurochem 106:1483-1492.

Denny JB (2006) Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43. Curr Neuropharmacol 4:293-304.

Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood A, Geoffroy CG, Zheng B, Liepmann CD, Katagiri Y, Benowiz LI, Geller HM, Giger RJ (2012) NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci 15:703-712.

Dobbis R, Kalmanek E, Choe S, Harrington DA, Stupp SJ, McVary KT, Podlasek CA (2019) Sonic hedgehog regulation of cavernous nerve regeneration and neurite formation in aged pelvic plexus. Exp Neurology 312:10-19.

Eftekharpour E, Nagakannan R, Iqbal MA, Chen QM (2017) Mevalonate metabolism: functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J Neurosci 31:14051-14066.

Fujita Y, Takashima R, Endo S, Takai T, Yamashita T (2011) The p75 receptor mediates axon growth inhibition through an association with PIR-B. Cell Death Dis 2:e198.

Fujita Y, Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. Front Neurosci 8:338.

García-Sanz P, M F G Aerts J, Moratalla R (2020) The role of cholesterol in α-Synuclein and Lewy body pathology in GBA1 Parkinson’s disease. Mov Disord doi:10.1002/mds.28396.

González-Guevara E, Cáceres G, Pérez-Severiano F, Martínez-Lazcano JC (2020) Dysregulated brain cholesterol metabolism is linked to neuroinflammation in Huntington’s disease. Mov Disord 35:1113-1127.

Goodrum JF (1990) Cholesterol synthesis is down-regulated during regeneration of peripheral nerve. J Neurochem 54:1709-1715.

Goodrum JF, Brown JC, Fowler KA, Bouldin TW (2000) Axonal regeneration, but not myelination, is partially dependent on local cholesterol reutilization in regenerating nerve. J Neuropathol Exp Neuro 59:1002-1010.

Hammond N, Munkaci AB, Sturley SL (2019) The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease. Biochim Biophys Acta Mol Cell Biol Lipids 1864:1109-1123.

Hata K, Fujitani M, Yasuda Y, Doya H, Saito T, Yamagishi S, Mueller BK, Yamashita T (2006) RGMa inhibition promotes axonal growth and recovery after spinal cord injury. J Cell Biol 173:47-58.

Heybrock S, Kanerva K, Meng Y, Ing C, Liang A, Xiong Z, Weng X, Ah Kim Y, Collins R, Trimble W, Pomès R, Privé GG, Annaert W, Schwake M, Heeren J, Lüllmann-Rauch R, Grinstein S, Ikonen E, Saftig P, Neculai D (2019) Lysoosomal integral membrane protein-2 (LIIMP-2) is involved in lysosomal cholesterol export. Nat Commun 10:3521.

Higuchi H, Yamashita T, Yoshikawa H, Tohyama M (2003) PKA phosphorylates the p75 receptor and regulates its localization to lipid rafts. EMBO J 22:1790-1800.

Holmberg E, Nordstrom T, Gross M, Kluge B, Zhang SX, Doolen S (2006) Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J Neurotrauma 23:1366-1378.

Kempf A, Tews B, Arzt ME, Weinmann O, Obermair FJ, Pernet V, Zagrebelsky M, Delerak A, Iobb C, Zemmar A, Ristic Z, Gullo M, Spies P, Dodd D, Gygax D, Korte M, Schwab ME (2014) The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol 12:e1001763.

Kopp MA, Brommer B, Gatzemeier N, Schwab JM, Prüss H (2010) Spinal cord injury induces differential expression of the profibrotic semaphorin 7A in the developing and mature glial scar. Glia 58:1748-1756.

Korinek M, Gonzalez-Gonzalez JM, Smekalova T, Hajdukovic D, Skenkova K, Krusek J, Horak M, Vyklicky L (2020) Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission. Sci Rep 10:12651.

Krivoi P, Petrov AM (2019) Cholesterol and the safety factor for neuromuscular transmission. Int J Mol Sci 20. doi:10.3390/ijms20051046.

Langness VF, van der Kant R, Das U, Wang L, Chaves RDS, Goldstein LSB (2021) Cholesterol lowering drugs reduce APP processing to Aβ by inducing APP dimerization. Mol Biol Cell 32:247-259.

Lee J, Shin JE, Lee B, Kim H, Jeon Y, Ahn SH, Chi SW, Cho Y (2020) The stem cell marker Prom1 promotes axon regeneration by down-regulating cholesterol synthesis via Smad signaling. Proc Natl Acad Sci U S A 117:15955-15966.

Levental I, Levental KR, Heberle FA (2020) Lipid rafts: controversies resolved, mysteries remain. Trends Cell Biol 30:341-353.

Li H, Kuwajima T, Oakley D, Nikulina E, Hou J, Yang WS, Lowry ER, Lamas NJ, Amoroso MW, Croft GF, Hosur R, Wichterle H, Sebti S, Filbin MT, Stockwell B, Henderson CE (2016) Protein prenylation constitutes an endogenous brake on axonal growth. Cell Rep 14:10-19.

Liu L, Yuan H, Yi Y, Koellhoffer EC, Munshi Y, Bu F, Zhang Y, Zhang Z, McCullough LD, Li J (2018) Ras-related C3 Botulinum toxin substrate 1 promotes axonal regeneration after stroke in mice. Tranl Stroke Res 9:506-514.

Miller WL (2017) Steroidogenesis: Unanswered questions. Trends Endocrinol Metab 28:771-793.

Mollinedo F, Gajate C (2020) Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy. J Lipid Res 61:611-635.

Ohashi K, Ojima J, Tozawa R, Kitamine T, Yagyu H, Sekiya M, Tomita S, Okazaki H, Tamura Y, Yahagi N, Iizuka Y, Harada K, Gotoda T, Shimano H, Yamada N, Ishihashi S (2003) Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. J Biol Chem 278:42936-42941.
Review

Orlova VV, Chuva de Sousa Lopes S, Valdimarsdottir G (2016) BMP-SMAD signaling: From pluripotent stem cells to cardiovascular commitment. Cytokine Growth Factor Rev 27:55-63.

Quraishi S, Forbes LH, Andrews MR (2018) The extracellular environment of the CNS: Influence on plasticity, sprouting, and axonal regeneration after spinal cord injury. Neural Plast 2018:2952386.

Reddy JM, Raut NGR, Seifert JL, Hynds DL (2020) Regulation of small GTPase prenylation in the nervous system. Mol Neurobiol 57:2220-2231.

Riobo NA (2012) Cholesterol and its derivatives in Sonic Hedgehog signaling and cancer. Curr Opin Pharmacol 12:736-741.

Rodemer W, Gallo G, Selzer ME (2020) Mechanisms of axon elongation following CNS injury: What is happening at the axon tip? Front Cell Neurosci 14:177.

Roet KCD, Franssen EHP, de Bree FM, Essing AHW, Zijlstra SJJ, Fagoe ND, Eggerink HM, Eggers R, Smit AB, van Kesteren RE, Verhaagen J (2013) A multilevel screening strategy defines a molecular fingerprint of prorregenerative olfactory ensheathing cells and identifies SCAR82, a protein that improves regenerative sprouting of injured sensory spinal axons. J Neurosci 33:11116-11135.

Roselló-Busquets C, de la Oliva N, Martínez-Mármol R, Hernaíz-Llorens M, Pascual M, Muñaisen A, Navarro X, Del Valle J, Soriano E (2019) Cholesterol depletion regulates axonal growth and enhances central and peripheral neuroregeneration. Front Cell Neurosci 13:40.

Roselló-Busquets C, Hernaíz-Llorens M, Soriano E, Martínez-Mármol R (2020) Nystatin regulates axonal extension and regeneration by modifying the levels of nitric oxide. Front Mol Neurosci 13:56.

Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR (2017) The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis 32:949-965.

Saher G, Simons M (2010) Cholesterol and myelin biogenesis. Subcell Biochem 51:489-508.

Saher G, Stumpf SK (2015) Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim Biophys Acta 1851:1083-1094.

Sáiz-Vázquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J (2020) Cholesterol and Alzheimer’s disease risk: a meta-meta-analysis. Brain Sci doi:10.3390/brainsci10060386.

Samant NP, Gupta GL (2020) Novel therapeutic strategies for Alzheimer’s disease targeting brain cholesterol homeostasis. Eur J Neurosci doi:10.1111/ejn.14949.

Schneider SA, Tahirovic S, Hardy J, Strupp M, Bremova-Ertl T, Monnier PP (2014) Novel therapeutic strategies for Alzheimer’s disease targeting brain cholesterol homeostasis. Eur J Neurosci doi:10.1111/ejn.14949.

Scott-Solomon E, Kuruvilla R (2020) Prenylation of axonally translated Rac1 controls NGF-dependent axon growth. Dev Cell 53:691-705.

Shabanzadeh AP, Charish J, Tassew NG, Farhani N, Feng J, Qin X, Sugita S, Mothe AJ, Wälchli T, Koeberle PD, Monnier PP (2021) Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system. Neurobiol Dis doi:10.1016/j.nbd.2021.105259.

Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, He Z, Silver J, Flanagan JG (2009) PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 326:592-596.

Silver DI, Silver J (2014) Contributions of chondroitin sulfate proteoglycans to neurodevelopment, injury, and cancer. Curr Opin Neurobiol 27:171-178.

Subczynski WK, Pasenkiewicz-Gierula M, Widomska J, Mainali L, Raguz M (2017) High cholesterol/low cholesterol: Effects in biological membranes: a review. Cell Biochem Biophys 75:369-385.

Sviridov D, Mukhamedova N, Miller YI (2020) Lipid rafts as a therapeutic target. J Lipid Res 61:687-695.

Tassew NG, Mothe AJ, Shabanzadeh AP, Banerjee P, Koeberle PD, Bremrer R, Tator CH, Monnier PP (2014) Modifying lipid rafts promotes regeneration and functional recovery. Cell Rep 8:1146-1159.

Um JW, Ko J (2017) Neural glycosphosphatidylinositol-anchored proteins in synaptic specification. Trends Cell Biol 27:931-945.

Uyeda A, Muramatsu R (2020) Molecular mechanisms of central nervous system axonal regeneration and remyelination: a review. Int J Mol Sci doi:10.3390/ijms21218116.

Vance JE, Campenot RB, Vance DE (2000) The synthesis and transport of lipids for axonal growth and nerve regeneration. Biochim Biophys Acta 1486:84-96.

Vance JE, Pan D, Vance DE, Campenot RB (1991) Biosynthesis of membrane lipids in rat axons. J Cell Biol 115:1061-1068.

Villarroel-Campos D, Bronfman FC, Gonzalez-Billaut C (2016) Rab GTPase signaling in neurite outgrowth and axon specification. Cytoskeleton (Hoboken, N.J.) 73:498-507.

Wang D, Zheng W (2015) Dietary cholesterol concentration affects synaptic plasticity and dendrite spine morphology of rabbit hippocampal neurons. Brain Res 1622:350-360.

Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420:74-78.

Whitlon DS, Grover M, Dunne SF, Richter S, Luan CH, Richter CP (2015) Novel high content screen detects compounds that promote neurite regeneration from cochlear spiral ganglion neurons. Sci Rep doi:10.1038/srep15960.

Wong ST, Henley JR, Kanning KC, Huang KH, Bothwell M, Poo MM (2002) A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci 1302-1308.

Yamada Y, Ohazama A, Maeda T, Seo K (2018) The Sonic Hedgehog signaling pathway regulates inferior alveolar nerve regeneration. Neurosci Lett 671:114-119.

Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617-627.

Yu W, Guo W, Feng L (2004) Segregation of Nogo66 receptors into lipid rafts in axons. J Neurosci 33:11116-11135.

Zhong W, Chen S, Tan X, Wang Z, Zhang X, He Z (2001) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2:90-100.

—P-Reviewer: Francisco-Morcillo J; C-Editors: Zhao M, Qiu Y; T-Editor: Jia Y